Tenaya Therapeutics is trading 5.14% lower now at $0.57; the cause of the October 1, 2026 decline remains unconfirmed. - No company-specific announcement or confirmed catalyst was found; the latest identified company news was the September 14 FDA RMAT designation for TN-401, before this move. - Broader markets were modestly lower, but supplied index moves were below 0.5% and do not establish a clear market-wide explanation.